Research programme: abuse-resistant therapeutics - Acura Pharmaceuticals

Drug Profile

Research programme: abuse-resistant therapeutics - Acura Pharmaceuticals

Latest Information Update: 29 Aug 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Acura Pharmaceuticals
  • Class Benzodiazepines
  • Mechanism of Action Central nervous system stimulants; GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Attention-deficit hyperactivity disorder

Most Recent Events

  • 01 Mar 2013 Discontinued - Preclinical for Anxiety disorders in USA (PO)
  • 01 Mar 2013 Discontinued - Preclinical for Attention-deficit hyperactivity disorder in USA (PO)
  • 30 Jun 2011 Preclinical trials in Attention-deficit hyperactivity disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top